Current approaches to therapy of ALK-positive non-small cell lung cancer

Por К. К. Laktionov, S Yu. Kruteleva, Е. V. Reutova
Publicado em 2021-06-01

Efficacy of lorlatinib in the treatment of ALK-positive non-small cell lung cancer patients with progression on crizotinib: personal experience

Por K. K. Laktionov, E. V. Reutova, S. Yu. Kruteleva, E. Yu. Antonova
Publicado em 2021-12-01

Immuno-related endocrinopathy in patients treated with immune checkpoint inhibitors

Por D. I. Yudin, K. K. Laktionov, K. A. Sarantseva, O. I. Borisova, V. V. Breder, E. V. Reutova, M. F. Beloyartseva, S. Yu. Kruteleva, I. A. Dzhanyan
Publicado em 2020-07-01